Article

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2

2022-03-28

Abstract excerpt

<h4>ABSTRACT</h4> Monoclonal antibodies targeting the SARS-CoV-2 spike (S) glycoprotein neutralize infection and are efficacious for the treatment of mild-to-moderate COVID-19. However, SARS-CoV-2 variants have emerged that partially or fully escape monoclonal antibodies in clinical use. Notably, the BA.2 sublineage of B.1.1.529/omicron escapes nearly all monoclonal antibodies currently authorized for therapeutic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4b6a3007-67e8-5a7d-b657-871b69eb6bdf
DOI: 10.1101/2022.03.28.486075

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2DOI 10.1101/2022.03.28.486075Read

ACE2-based decoy receptors for SARS coronavirus 2.Semantic proximity Read

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variantsSemantic proximity Read

Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection <i>in vitro</i> and <i>in vivo</i>Semantic proximity Read

Redirection of SARS-CoV-2 to Phagocytes by Intranasal sACE2-Fc as a Universal Decoy Confers Complete Prophylactic ProtectionSemantic proximity Read

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activitiesSemantic proximity Read

ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for <i>in vivo</i> efficacy against SARS-CoV-2Semantic proximity Read

Protein Scaffold‐Based Multimerization of Soluble ACE2 Efficiently Blocks SARS‐CoV‐2 Infection In Vitro and In VivoSemantic proximity Read

Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infectionSemantic proximity Read

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read

ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2Semantic proximity Read

Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptidesSemantic proximity Read

Broadly effective ACE2 decoy proteins protect mice from lethal SARS-CoV-2 infectionSemantic proximity Read